John A. Lewicki Sells 4,557 Shares of OncoMed Pharmaceuticals, Inc. (OMED) Stock
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) CEO John A. Lewicki sold 4,557 shares of the company’s stock in a transaction dated Tuesday, April 24th. The stock was sold at an average price of $2.68, for a total transaction of $12,212.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
NASDAQ OMED opened at $3.09 on Friday. OncoMed Pharmaceuticals, Inc. has a 52 week low of $1.74 and a 52 week high of $5.56.
OncoMed Pharmaceuticals (NASDAQ:OMED) last posted its earnings results on Thursday, March 8th. The biopharmaceutical company reported $0.25 EPS for the quarter, topping the consensus estimate of ($0.34) by $0.59. The firm had revenue of $20.64 million during the quarter, compared to the consensus estimate of $5.10 million. equities research analysts expect that OncoMed Pharmaceuticals, Inc. will post -0.96 EPS for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Endurant Capital Management LP bought a new position in shares of OncoMed Pharmaceuticals in the fourth quarter valued at approximately $570,000. Crestline Management LP bought a new position in shares of OncoMed Pharmaceuticals in the fourth quarter valued at approximately $753,000. Millennium Management LLC boosted its holdings in shares of OncoMed Pharmaceuticals by 148.7% in the fourth quarter. Millennium Management LLC now owns 543,335 shares of the biopharmaceutical company’s stock valued at $2,228,000 after acquiring an additional 324,845 shares in the last quarter. Paloma Partners Management Co bought a new position in shares of OncoMed Pharmaceuticals in the fourth quarter valued at approximately $135,000. Finally, Perceptive Advisors LLC boosted its holdings in shares of OncoMed Pharmaceuticals by 152.4% in the fourth quarter. Perceptive Advisors LLC now owns 2,620,897 shares of the biopharmaceutical company’s stock valued at $10,745,000 after acquiring an additional 1,582,608 shares in the last quarter. Institutional investors and hedge funds own 53.62% of the company’s stock.
OncoMed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc discovers and develops cancer stem cell (CSC) and immuno-oncology therapeutics. The company's product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer.
Receive News & Ratings for OncoMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.